 |
|
|
| |
Merck HCV Protease MK-7009
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2009, Boston, MA
Of note, treatment-naïve patients in this study received MK-7009+peg/rbv for 4 weeks only but received peg/rbv after 4 weeks for a total of 12 weeks therapy, but after 12 weeks 77-89% of patients were undetectable. The safety profile looked good.
"Early Viral Response Rates in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Infection Treated with MK-7009, a novel NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days"
Michael Manns presenter
Protocol 007 Study Group
Patients received 1 of 4 MK-7009 regimens 300 bid, 600 bid, 600 qd or 800 qd all with peg/rbv, MK-7009 was administered only for the first 4 weeks.
|
| |
|
|
|
|
|
